Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
The MMR vaccine contains three live, weakened viruses: measles (Enders' Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain), grown in chick embryo cell culture and human diploid lung fibroblast cells. Supporting ingredients include stabilizers and sugars (sorbitol, sucrose, hydrolyzed gelatin, recombinant human albumin), growth media and salts (Medium 199 with Hanks' salts, Minimum Essential Medium, sodium phosphate, sodium chloride, sodium bicarbonate, monosodium L-glutamate), trace neomycin as an antibiotic, phenol red as a pH indicator, and residual fetal bovine serum. Notably, it contains no thimerosal or mercury-based preservative, though trace amounts and allergy considerations (gelatin, neomycin, egg-related concerns) matter for some people. There are several important details, including quantities and who should talk to a doctor first, so see below to understand more.
If you are weighing this vaccine because of symptoms you or your child are experiencing, guessing rarely brings peace of mind. A free, instant, online symptom check asks targeted questions about what you are feeling, helps you see which conditions fit the pattern, and points you toward the right next step, whether that is reassurance, a pharmacy visit, or prompt medical care.
Last reviewed for medical accuracy: 10/01/2025
If you’ve ever wondered “what is in the MMR vaccine,” you’re not alone. The MMR vaccine protects against measles, mumps and rubella—three viruses that once caused serious illness worldwide. Below, you’ll find a clear, ingredient-by-ingredient look at what makes up today’s MMR vaccine, based solely on credible sources such as the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA).
The heart of the MMR vaccine is three live, weakened (attenuated) viruses. They’re strong enough to teach your immune system how to fight measles, mumps and rubella—but too weak to cause full-blown disease in healthy people.
Measles virus (live attenuated)
Stimulates immunity to measles. Each 0.5 mL dose contains at least 1,000 CCID50 (cell culture infectious dose).
Mumps virus (live attenuated)
Trains your body to recognize mumps. Each dose contains at least 5,000 CCID50.
Rubella virus (live attenuated)
Builds protection against rubella (“German measles”). Each dose contains at least 1,000 PFU (plaque-forming units).
To keep these delicate viruses alive and effective from manufacture through injection, the vaccine includes several stabilizers and buffering salts:
Sorbitol
A sugar alcohol that helps protect viral particles during freezing and thawing.
Hydrolyzed porcine gelatin
A protein derived from pork that stabilizes the vaccine’s structure and prevents clumping.
Monosodium L-glutamate (MSG)
Not to be confused with the food additive controversy—here, it acts as a buffering agent to maintain the right pH.
Salts (phosphate-buffered saline)
During the vaccine’s production, tiny amounts of antibiotic are used to prevent bacterial contamination in the cell cultures where the viruses grow. What remains in the final product is far below levels known to cause allergic reactions in almost everyone.
Because the viruses are grown in chicken embryo fibroblast cultures, you may find minute amounts of proteins from those cells, plus traces of bovine (cow) serum used in the growth medium.
These are present at extremely low levels (micrograms per dose) and have not been linked to health problems in people without severe egg allergies.
Unlike some older vaccines, modern MMR doses do not contain preservatives such as thimerosal. Each 0.5 mL dose is supplied in a single-use vial or syringe.
Common reactions are mild and short-lived, such as:
Serious reactions are very rare. If you ever feel unwell after vaccination, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
No vaccine is 100% risk-free, but the benefits of preventing measles, mumps and rubella far outweigh the small chance of side effects. If you’re unsure whether MMR is right for you or your child—especially if there’s a history of severe allergies or immune problems—always speak to a doctor.
Remember, nothing in this summary replaces personalized medical advice. For any life-threatening or serious symptoms, contact emergency services or see your healthcare provider immediately.
This information is based on official U.S. vaccine guidelines and peer-reviewed data. Always consult a healthcare professional for medical decisions.
(References)
* Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Dev Biol Stand. 1986;65:85-8. PMID: 3030863.
* Nabe-Nielsen J, Walter B. Unilateral total deafness as a complication of the measles-mumps-rubella vaccination. Scand Audiol Suppl. 1988;30:69-70. PMID: 3227284.
* Kelso JM. The gelatin story. J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):200-2. doi: 10.1016/s0091-6749(99)70490-2. PMID: 9949308.
* Wandel G. Mumps component in combined measles, mumps, and rubella vaccines. Vaccine. 1999 Feb 12;17(6):511. doi: 10.1016/s0264-410x(98)00309-0. PMID: 10075156.
* Isaacs D, Lawrence G, Boyd I, Ronaldson K, McEwen J. Reporting of adverse events following immunization in Australia. J Paediatr Child Health. 2005 Apr;41(4):163-6. doi: 10.1111/j.1440-1754.2005.00580.x. PMID: 15813867.
* De Laval F, Haus R, Spiegel A, Simon F. Lower long-term immunogenicity of mumps component after MMR vaccine. Pediatr Infect Dis J. 2010 Nov;29(11):1062-3; author reply 1063. doi: 10.1097/INF.0b013e3181f2d864. PMID: 20975455.
* Malaiyan J, Duraipandian T, Warrier A, Menon T. Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India. Indian J Med Res. 2014 Jun;139(6):949-51. PMID: 25109732; PMCID: PMC4165010.
* Chai ZT, Goh JY, Choo KJL, Ong KY, Tan V, Chong CJ, Naing CS, Lee HY. Evaluation of patients with suspected vaccine allergies in Singapore. Asian Pac J Allergy Immunol. 2025 Sep;43(3):569-574. doi: 10.12932/AP-140724-1891. PMID: 40321139.
* Nakasuwan K, Chaisavaneeyakorn S, Pakakasama S, Techasaensiri C, Apiwattanakul N, Boonsathorn S. Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy. BMC Res Notes. 2025 Dec 19;19(1):39. doi: 10.1186/s13104-025-07617-1. Epub 2025 Dec 19. PMID: 41419933; PMCID: PMC12831313.
* Iordachescu M, El Abd K. [Anaphylaxis to MMR vaccine gelatin : practical recommendations]. Rev Med Liege. 2026 Sep;81(9):528-535. PMID: 42751843.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.